The global Anorexiant market size was valued at over US$ 1 billion in 2022. Over the projection period, the Anorexiants market is expected to increase at a CAGR of 5.3%. The rising prevalence of obesity can be attributed to growth. The United States climbed from 35% to 41.9% from 1990 to 2000 to 2017 to 2020, according to CDC data released in May 2022.
According to the WHO, 39 million children under the age of five, as well as nearly 600 million adults, will be obese by 2021. This factor is boosting healthcare cost, which is expected to drive Anorexiant demand in the next years.
Request a report sample to gain comprehensive insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9574
Anorexiants: Market Insights
Anorexiants are used to treat obesity. Anorexiants suppress hunger by boosting a person’s basal metabolic rate. Anorexiants also boost cellular glucose uptake while lowering fat absorption from food.
According to the World Health Organisation, more than 1.9 billion people aged 18 and older were classified as overweight in 2016, with 650 million adults classified as obese. In addition, 41 million children under the age of five were found to be obese in 2016.
Anorexiants: Market Dynamics
Because of their utility in the treatment of obesity, anorexiants are expected to grow greatly in the market. Anorexiants can aid in weight loss by reducing calorie intake, particularly in patients with a BMI of 30 or higher.
The market is expected to grow because anorexiants are used to treat obesity. Anorexics, on the other hand, are restricted in some ways. Anorexiants can have a number of unpleasant side effects, including sleepiness, elevated blood pressure, restlessness, drug dependence, and so on, which can have an effect on the Anorexiants market. Long-term use of anorexiants also leads to drug addiction, which can lead to health concerns later in life.
For critical insights on this market, request to ask an expert here@ https://www.futuremarketinsights.com/ask-question/rep-gb-9574
Anorexiants Market: Overview
Because of the rising prevalence of obesity around the world, the Anorexiants industry is expected to produce significant income in the next years. Orlistat, lorcaserinER, liraglutide, naltrexone/bupropion ER, lorcaserin, and phentermine/topiramate ER are some of the anorexiants used to treat obesity. Many drugs have been approved by the FDA for the treatment of obesity, therefore the market for anorexiants is projected to grow in the coming years.
According to the Centres for Disease Control and Prevention, the obesity prevalence in the United States is expected to be 39.8%, affecting 93.3 million people. The global Anorexiants market will grow as the prevalence and incidence of weight gain and obesity rise.
Anorexiants Market: Region-wise Outlook
Geographically, the global Anorexiants market is segmented into seven primary regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific except Japan, Japan, and the Middle East and Africa. Because of the rising prevalence of obesity and the rapid adoption of new medications, North America is expected to hold the highest proportion of the Anorexiants market.
Furthermore, the expansion of healthcare facilities and technological improvements have substantially aided the Anorexiants industry. Europe is predicted to make a considerable contribution to the Anorexiants market due to increased drug launches and easier drug approval, resulting in market growth.
Anorexiants Market: Key Players
Some of the key players present across the value chain of the global Anorexiants market are Akrimax Pharmaceuticals, LLC, Teva Pharmaceuticals, Janssen Ortho, LLC, Roche Pharmaceuticals, Arena Pharmaceuticals GmbH, Novo Nordisk A/S, Abbott Pharmaceuticals PR Ltd., Epic Pharma, LLC. Patheon Pharmaceuticals Inc. Catalent Pharma Solutions, LLC, Recordati Rare Diseases Inc., MOVA Pharmaceuticals.
For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/9574
Key Segments Profiled in the Anorexiants Market Survey
By Drug Class:
- Catecholaminesb
- Serotoninb
By Route of Administration:
- Oral
- Subcutaneous
By End User:
- Institutional sales
- Hospitals
- Clinics
- Retail sales
- Online pharmacies
- Mail Order Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
